Table 4 Comparison between patients with or without IM
Characteristics | Case (n = 32) | Control (n = 64) | P value |
|---|---|---|---|
Demographic characteristics | |||
Sex, male to female | 7:25 | 15:49 | 0.86 |
Age, years, mean ± SD | 42.4 ± 15.8 | 45.5 ± 17.5 | 0.44 |
Duration of CTD, months, median (IQR) | 6.0(1.0,75.0) | 24.0(7.5,87.0) | 0.19 |
Diabetes mellitus, n (%) | 4(12.5) | 3(4.7) | 0.17 |
Interstitial pneumonia, n (%) | 6(18.8) | 2(3.1) | 0.01* |
Nephritis, n (%) | 19(59.4) | 29(45.3) | 0.19 |
Laboratory data | |||
Leukopenia, n (%) | 4(12.5) | 11(17.2) | 0.55 |
Lymphopenia, n (%) | 23(71.9) | 27(42.2) | 0.01* |
Anemia, n (%) | 20(62.5) | 38(59.4) | 0.77 |
Hypoalbuminemia, n (%) | 23(71.9) | 42(75.0) | 0.75 |
Elevated serum creatinine, n (%) | 13(40.6) | 18(28.1) | 0.22 |
IgM (g/l), median (IQR) | 0.6(0.3,1.0) | 0.8(0.5,1.3) | 0.09 |
IgG (g/l), median (IQR) | 14.1(10.3,17.3) | 13.1(8.9,17.9) | 0.77 |
ESR (mm/h),median (IQR) | 56.0(40,66) | 27.0(13,58) | 0.01* |
CRP (mg/l), median (IQR) | 11.7(5.0,37.0) | 2.9(0.9,14.3) | 0.002* |
Treatments prior to IM | |||
Median-to-high dose of GC, n (%) | 11(34.4) | 6(9.4) | < 0.001* |
CYC, n (%) | 9(28.1) | 8(12.5) | 0.06 |
MMF, n (%) | 3(9.4) | 8(12.5) | 0.65 |
CsA, n (%) | 3(9.4) | 8(12.5) | 0.65 |
MTX, n (%) | 2(6.3) | 6(9.4) | 0.60 |